ArticleCardiovascular diabetology2025
Association between triglyceride-glucose index combined with a body shape index and atherosclerotic cardiovascular disease risk varies by glycemic status: insights from the UK Biobank.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Predictive value of the triglyceride glucose index-a body shape index (TyG-ABSI) for cardiovascular disease and its comparison with other TyG-related obesity indices: a study based on the China health and retirement longitudinal study (CHARLS) cohort.Cardiovascular diabetology · 2026Article
- Sex-Specific Associations of Triglyceride-Glucose Index and a Body Shape Index with Cardiometabolic Multimorbidity Risk: A Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study.Cardiovascular diabetology · 2026Article
- Unmasking silent bioenergetic failure in normolactatemic AMI patients: a multicenter validation of the TyG-ACAG index.Lipids in health and disease · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies.Cardiovascular diabetology · 2026Article
- Triglyceride glucose index-a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe triglyceride-glucose (TyG) index, a measure of insulin resistance, has been confirmed to be associated with adverse clinical outcomes. A new composite indicator, the TyG-A body type index (TyG-ABSI), was developed by integrating the TyG index and the A body type index. This study aimed to thoroughly investigate the association between the TyG-ABSI and the risk of atherosclerotic cardiovascular disease (ASCVD) among individuals with normoglycemia, dysglycemia, and diabetes.
methodsParticipants from the UK Biobank were included and categorized into 3 groups: normoglycemia, dysglycemia (prediabetes), and diabetes. The primary study outcome was the incidence of all-cause ASCVD. Cox regression and restricted cubic spline (RCS) analyses were performed to evaluate the linear and nonlinear associations between the TyG-ABSI and ASCVD. Furthermore, time-dependent receiver operating characteristic (ROC) curves were constructed to evaluate the discriminative performance of the TyG-ABSI and other indices. Additional analyses, including Kaplan-Meier survival curves, subgroup analyses, and sensitivity analyses, were conducted to assess robustness. A mediation analysis was performed to identify potential biomarkers.
resultsDuring an average follow-up of 14.8 years, a total of 29,680 ASCVD events were documented. The results indicated that elevated TyG-ABSI values were positively associated with the risk of ASCVD in the population with normoglycemia (nonlinear, P for nonlinear < 0.001) and diabetes (linear, P for nonlinear = 0.96) (HR = 1.07, 95% CI: 1.05-1.09; HR = 1.10, 95% CI: 1.06-1.14, respectively). No significant associations were detected in the dysglycemia group. Compared with the TyG index and other TyG-derived metrics, the TyG-ABSI demonstrated superior predictive performance (e.g., 10-year AUC = 0.634 in the normoglycemia group). Subgroup analyses and sensitivity analyses confirmed the robustness of our findings. Moreover, the results of the mediation analysis demonstrated that white blood cell (WBC) count (mediation proportions: 3.74-9.73%) and C-reactive protein (CRP) level (mediation proportions: 9.96-26.89%) significantly mediated the association between the TyG-ABSI and ASCVD.
conclusionsIn the normoglycemia subgroup, the association between the TyG-ABSI and ASCVD was nonlinear. Moreover, the TyG-ABSI was linearly associated with an increased risk of ASCVD in the diabetes subgroup but not in the dysglycemia subgroup. The predictive value of the TyG-ABSI across different glycemic statuses provides new evidence for medical practice. Furthermore, the TyG-ABSI may serve as a useful tool for identifying high-risk individuals within the seemingly low-risk normoglycemic population and for further risk identification among diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.